SUMMARY The effects of indoramin, a selective alpha1 adrenoceptor antagonist, on exercise tolerance were studied in 15 patients using a random double blind crossover protocol. All patients had chronic stable angina, for which 13 had been receiving beta adrenoceptor blocking drugs and nitrates, and these were continued unchanged throughout the study. An initial open challenge with indoramin in eight patients with chronic stable angina showed no serious adverse effects. In a dose of 25 mg three times daily indoramin prolonged exercise duration and increased oxygen consumption during exercise, while the maximal double product was unchanged. The increased exercise capacity was associated with a reduction in ST segment depression during exercise. Side effects included failure of ejaculation in one patient and tiredness in five.
Medical treatment of angina pectoris remains inadequate for many patients, despite the introduction of beta adrenoceptor blocking agents, long acting nitrates, and calcium antagonists. In addition, the side effects of these drugs-for example, bronchospasm, headache, and myocardial depression respectively-may limit their use in individual patients. The Total body oxygen consumption was continuously measured during each exercise test using a PK Morgan oxygen analyser Model 500. This was used as a direct measure of total body work and hence an indirect measure of myocardial work during exercise.
Results were expressed as mean (standard error of mean) and comparisons were made using analysis of variance.
Results
Results of the pilot study showed that indoramin in doses of 25 mg twice daily to 50 mg twice daily had no appreciable adverse effects on these patients. Table 2 Collins, Sheridan Improvement in angina pectoris with alpha adrenoceptor blockade rest to 112 (3) beats/min at peak exercise during placebo treatment. Heart rate at peak exercise was slightly increased by indoramin (to 118 (5) beats/min from 68 (4) beats/min at rest). The rise in mean systolic pressure at peak exercise was also affected little by indoramin (161 (8) mm Hg compared with 164 (6.6) mm Hg with placebo). Thus the rate pressure product at peak exercise was not significantly affected by indoramin (18934 (1263) compared with 18311 (795) with placebo).
ST SEGMENT CHANGES Figure 2 shows the changes in ST segment during exercise. Prolongation in exercise capacity was associated with a significant reduction in ST depression at three minutes (p<002) and six minutes (p<0.005) of exercise. In this study, exercise capacity before the onset of angina was improved, as indicated by increases in exercise duration and oxygen consumption during exercise. In contrast, the maximal double product changed little. These findings indicate that indoramin significantly increased total work but that cardiac work was similar at maximal exercise with placebo and active treatment. This implies that cardiac work at lower workloads was reduced by the drug, and the reduction in ST segment depression at three and six minutes of exercise supports this. This in turn suggests that the antianginal effect observed here reflects actions of the drug on peripheral arterioles and veins; however, further work is needed to clarify this. Indoramin frequently produced tiredness in the present study, and one patient withdrew for this reason. Serious cardiovascular side effects such as hypotension or worsening of angina did not occur. The incidence of side effects observed here was lower than in previous studies, in which higher doses were used to treat hypertension,'4 but is comparable with previous studies using calcium antagonists'5 and beta adrenoceptor antagonists. '6 17 In conclusion alpha adrenoceptor blockade with indoramin produced significant improvement in exercise capacity in patients already receiving beta blockers and nitrates. Further work is needed to establish whether or not this is a general property of alpha adrenoceptor blockade and to determine its haemodynamic mode of action.
